NDA 021057 · Organon USA Organon
Ganirelix Acetate
Ganirelix Acetate · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Jul 29, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
75
16 Phase 3, 4 recruiting
FAERS reports
719
327 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 29, 2026.
INDICATIONS AND USAGE Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- GANIRELIX ACETATE · GANIRELIX ACETATE 250MCG/0.5ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ganirelix" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00696800 · 1,509 participants · Start Jun 27, 2006 · Primary completion Nov 19, 2007
Drug: Corifollitropin alfa; RecFSH / Follitropin beta (Days 1 to 7) and 6 more · For: In Vitro Fertilization
- Short Versus Long Protocol for IVF and IVF+ICSIPivotal-lookingCompleted
Peter Hornnes, MD, DMScAcademic, hospital or other
NCT00756028 · 1,099 participants · Start Jan 2009 · Primary completion Dec 2014
Drug: Patients receiving short protocol IVF/ICSI-treatment.; Long protocol · For: Infertility; Ovarian Hyperstimulation Syndrome; Quality of Life and 1 more
Sites: Dronninglund, Denmark; Hvidovre, Denmark
- Letrozole in Stimulated IVF CyclesPivotal-lookingCompleted
The University of Hong KongAcademic, hospital or other
NCT02912988 · 900 participants · Start Mar 1, 2018 · Primary completion Apr 30, 2022
Drug: Letrozole · For: Subfertility
Sites: Hong Kong, China; Beijing, China
- Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian ResponsePivotal-lookingCompleted
ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
NCT04414761 · 784 participants · Start Jun 4, 2020 · Primary completion Oct 10, 2022
Drug: Progesterone; GnRH Antagonist · For: IVF; GnRH Antagonist; PPOS
Sites: Shanghai, China
- Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response PatientPivotal-lookingCompleted
Reproductive & Genetic Hospital of CITIC-XiangyaAcademic, hospital or other
NCT03300518 · 552 participants · Start Nov 15, 2017 · Primary completion Jun 18, 2021
Drug: Follitropin Beta;MSD; Ganirelix and 2 more · For: Infertility
Sites: Changsha, China
- To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00702845 · 397 participants · Start Dec 28, 2006 · Primary completion Jul 7, 2007
Drug: corifollitropin alfa (Org 36286); recFSH (follitropin beta) and 6 more · For: Infertility
- The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation CyclesPivotal-lookingStatus unknown
Casa di Cura Privata Villa MafaldaResearch network
NCT04654741 · 396 participants (planned) · Start Sep 1, 2020 · Primary completion Feb 1, 2022
Drug: Medroxyprogesterone Acetate; Ganirelix Acetate · For: IVF; Infertility
Sites: Roma, Italy
- A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00598208 · 325 participants · Start May 19, 2003 · Primary completion Mar 15, 2004
Drug: corifollitropin alfa; Follitropin beta injection · For: Fertilization
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome225
- needle issue48
- ascites44
- nausea44
- no adverse event40
- poor quality device used40
- headache36
- injection site pain34
- drug ineffective31
- dyspnoea29
- fatigue29
- product quality issue28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 20 |
| 2014 | 48 |
| 2015 | 2 |
| 2016 | 8 |
| 2017 | 4 |
| 2018 | 24 |
| 2019 | 51 |
| 2020 | 31 |
| 2021 | 45 |
| 2022 | 114 |
| 2023 | 58 |
| 2024 | 101 |
| 2025 | 68 |
| 2026 | 143 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- ETB receptor-mediated vasodilation is regulated by estradiol in young women.
Shoemaker LN, Haigh KM, Kuczmarski AV, et al. · Am J Physiol Heart Circ Physiol 2021 · Clinical Trial, Research Support, N.I.H., Extramural
- GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
Yuan H, Zheng J, Wong HT, et al. · J Coll Physicians Surg Pak 2026 · Network Meta-Analysis, Review
- The effects of GnRH antagonist on the endometrium of normally menstruating women.
Sirayapiwat P, Suwajanakorn S, Triratanachat S, et al. · J Assist Reprod Genet 2007 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI.
Mochtar MH · Hum Reprod 2004 · Clinical Trial, Multicenter Study
- Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies.
Wilcox J, Potter D, Moore M, et al. · Fertil Steril 2005 · Clinical Trial, Phase IV, Comparative Study
- Correlation of LH level and steroid concentrations in GnRH antagonist protocol: A sub-analysis of Ganirelix phase III study of China.
Li R, Gong F, Chen H, et al. · J Gynecol Obstet Hum Reprod 2022 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.